ABMD Stock: Abiomed, Inc. Stock Price, Analysis & Insights
Get live abmd stock price $381.02, comprehensive Abiomed, Inc. stock analysis, charts, news, and expert forecast. Real-time abmd stock data and investment insights.
Loading chart...
Company Overview
Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite. It also provides Impella 5.0, Impella LD, and Impella 5.5, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; Impella Connect, a cloud-based technology that enables secure and remote viewing of the automated impella controller for physicians and hospital staffs; and OXY-1 System, a portable external respiratory assistance device. In addition, the company is developing Impella ECP, a pump for blood flow of greater than three liters per minute; Impella XR Sheath, a sheath that expands and recoils allowing small bore access and closure with Impella heart pumps; Impella BTR, a percutaneous micro heart pump with integrated motors and sensors; and preCARDIA, a catheter-mounted superior vena cava therapy system designed to rapidly treat acutely decompensated heart failure. Abiomed, Inc. sells its products through direct sales and clinical support personnel in the Germany, France, United States, Japan, Europe, Canada, Latin America, the Asia-Pacific, and the Middle East. The company was founded in 1981 and is headquartered in Danvers, Massachusetts. As of December 22, 2022, Abiomed, Inc. operates as a subsidiary of Johnson & Johnson.
Company Information
- CEO
- Michael Minogue
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 2003
Contact Information
- Website
- https://www.abiomed.com
- Address
- 22 CHERRY HILL DR
- Country
- US
Investment Analysis & Business Insights
Investment Highlights
✓ Strong presence in the Healthcare sector with established market position
✓ Growth-oriented company with premium valuation (P/E: 65.4)
✓ Lower volatility stock (Beta: 0.00) may provide portfolio stability
Business Model & Strategy
Abiomed, Inc. operates in the Medical - Devices industry, focusing on medical services, pharmaceutical development, and healthcare delivery. Under the leadership of CEO Michael Minogue, the company navigates Healthcare sector dynamics while pursuing growth opportunities. The Medical - Devices model requires regulatory compliance, research investment, and patient outcomes to maintain competitiveness and drive shareholder value.
Market Position & Competitive Landscape
Abiomed, Inc. competes in the Medical - Devices within the broader Healthcare. With 17.2 billion in market capitalization, the company is positioned as a established player in its sector. The Healthcare is characterized by demographic shifts, regulatory changes, and medical breakthroughs. As a publicly traded company on the NASDAQ Global Select, Abiomed, Inc. provides investors with liquidity and transparency while subject to regulatory oversight. Investors evaluating Abiomed, Inc. should consider industry-specific trends, competitive positioning, and Healthcare sector fundamentals.
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for Abiomed, Inc. shareholders
- ⚠Market volatility can significantly impact stock price, especially for mid-cap stocks
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for Abiomed, Inc.
- ⚠Investors should consider how Abiomed, Inc. fits within their overall portfolio allocation
- ⚠Premium valuation (P/E: 65.4) requires strong growth to justify
Market Cap
17.18B
P/E Ratio
65.36
Beta
0.00
Investment Analysis & Insights
Key Investment Highlights
- Market Position: Healthcare leader with 17.18B market capitalization
- Trading Volume: 15.70M shares traded today
- Price Range: 52-week range of $219.84 - $381.99
- Exchange: Listed on NASDAQ Global Select
Financial Metrics
Market Analysis for Abiomed, Inc.
Abiomed, Inc. (ABMD) operates in the Medical - Devices industry within the Healthcare sector. With a current market capitalization of 17.18B, the company represents a significant player in its market. The stock is currently trading at $381.02 with a positivedaily change of 0.00%.
The company's 2003 employee base and presence on the NASDAQ Global Selectexchange position it as a Healthcare sector leader. Investors should consider the stock's P/E ratio of 65.36, beta of 0.00, and 52-week price range from $219.84 to $381.99when evaluating investment opportunities.
Why Invest in Abiomed, Inc.?
Strengths
- • Established market presence in Healthcare
- • Strong financial metrics and market position
- • Listed on major exchange (NASDAQ Global Select)
- • Experienced leadership under Michael Minogue
Investment Considerations
- • Monitor sector-specific market trends
- • Track quarterly earnings performance
- • Consider market volatility and beta
- • Evaluate long-term growth potential
Related Healthcare Stocks
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.